Undeterred by domestic regulatory concerns, Hims & Hers is actively executing its global strategy. On December 10, the company launched its comprehensive weight-loss program in the United Kingdom, ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Eli Lilly and Company plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama.

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

In a strategic pivot, the company has launched its weight-loss program in the United Kingdom. There, Hims & Hers is offering legitimate, branded medications—Novo Nordisk's Wegovy and Eli Lilly's ...

Once construction is complete in 2032, the company plans on creating some of its "biggest medicines" at the new facility.

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.

Norfolk Southern will serve a new $6 billion Eli Lilly and Co. manufacturing campus that the pharmaceutical company will ...

Large pharmaceutical conglomerate Eli Lilly has announced plans to build a $6 billion manufacturing facility in Huntsville, Alabama. The site will focus on the production of small molecules and ...

Eli Lilly is investing $6B in a Huntsville, Ala., plant to make weight-loss and other medicines. Here’s what we know about jobs and timeline.

Eli Lilly plans API plant in Alabama to produce small molecule and peptide medicines, creating 450 jobs and enhancing U.S. pharmaceutical supply chains.

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...